Tecartus cleared for relapsed or refractory mantle cell lymphoma

What this means

Tecartus is a personalized cell therapy that modifies a patient's own immune cells to target and kill cancer cells. The FDA granted full approval for Tecartus to treat adults with mantle cell lymphoma that has returned or stopped responding to other treatments. This decision provides a new treatment option for patients with this rare and aggressive form of blood cancer.